More and more strict drug control, 20 heavyweight varieties will be stopped by a large number of hospitals

[industry trends of pharmaceutical network] on December 10, Fujian Medical Security Bureau issued a document saying that the online directory of joint price limit sunshine procurement will be adjusted by category It is worth noting that in one item of catalogue deletion, the varieties listed in the national key monitoring were deleted - 20 varieties, basically bid farewell to Fujian market In fact, since July 1, the State Administration issued the first batch of national key monitoring and rational drug use catalog, each province has successively released its own key monitoring catalog Some provinces directly follow the national version, while others make some adjustments based on the national version But to some extent, compared with other places, the strength of the policy in Fujian Province is still very large Directly deleting it from the catalog means that 20 varieties have withdrawn from the public hospital market of Fujian Province at least In fact, according to recent industry news, in addition to Fujian Province, hospitals in other provinces are clearing some of the key monitoring drugs out of the supply catalogue For example, in the first batch of "list of drugs listed in the list of drugs listed in the list of drugs listed in the list of drugs listed in the list of drugs listed in the list of drugs listed in the list of drugs listed in the list of drugs listed in the first batch of" list of drugs listed in the list of drugs listed in the list of drugs listed in the list of drugs listed in the list of drugs listed in the list of drugs listed in the list of drugs listed in the list of drugs listed in the list of drugs listed in the list of drugs Some time ago, a group of hospitals in Jiangsu Province began to implement the key monitoring drug program Take a top three hospital in Xuzhou as an example It requires doctors not to use more than two kinds of drugs in the catalog within 24 hours The top three months in the catalog will be stopped For some traditional Chinese medicine injections, the hospital said that "all of them have similar functions of promoting blood circulation and removing blood stasis and should not be used repeatedly", while the drugs for cardiovascular and cerebrovascular systems under key monitoring are "not recommended for cardiology"
In addition, according to the public notice on the list of selected and alternative drugs and drugs excluded from the list of centralized drug procurement and supply of public medical institutions in Zhoushan City issued by Zhejiang Zhoushan hospital, 68 products have been listed in the list of selected and alternative drugs for centralized procurement and supply, 10 products have been listed in the list of key monitored drugs in the city, and they have been excluded from the list of procurement items Record In fact, in accordance with the notice on further promoting the experience of deepening the reform of medical and health system in Fujian Province and Sanming City issued by the relevant departments on November 15, all provinces shall formulate and issue the provincial key monitoring and rational drug use catalogue (chemical and biological products) and publish it before the end of December 2019, and comprehensively establish the requirements of key drug monitoring mechanism before the end of December 2020 It can be predicted that in the next half of a month, more provinces will successively issue the list of drugs with emphasis on monitoring rational use of drugs On the whole, in the future, with the release of the key drug control catalogue of each province, the national and local drug control will be more and more strict In addition, the use of the key monitored varieties will continue to be squeezed nationwide This may lead to the possibility that the key monitored drugs will be temporarily suspended or simply abandoned after the second level hospital assessment is launched in full next year In this case, the relevant pharmaceutical companies should plan and adjust the industrial structure of the enterprises in advance without any preparation, so as to keep the industrial focus away from the drugs that have been restricted or may be added to the regulatory list in the future.